|
1
|
Overfed Ossabaw swine with early stage metabolic syndrome have normal coronary collateral development in response to chronic ischemia.
|
Basic Res Cardiol
|
2012
|
1.26
|
|
2
|
Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle.
|
Arch Surg
|
2011
|
1.14
|
|
3
|
Should aortas in patients with bicuspid aortic valve really be resected at an earlier stage than tricuspid? CON.
|
Cardiol Clin
|
2010
|
1.12
|
|
4
|
Effect of hydrogen sulfide in a porcine model of myocardial ischemia-reperfusion: comparison of different administration regimens and characterization of the cellular mechanisms of protection.
|
J Cardiovasc Pharmacol
|
2009
|
1.11
|
|
5
|
Effect of hypercholesterolemia on myocardial necrosis and apoptosis in the setting of ischemia-reperfusion.
|
Circulation
|
2009
|
1.10
|
|
6
|
Assessment of intramyocardial hemorrhage by T1-weighted cardiovascular magnetic resonance in reperfused acute myocardial infarction.
|
J Cardiovasc Magn Reson
|
2012
|
1.10
|
|
7
|
Resveratrol in the prevention and treatment of coronary artery disease.
|
Curr Atheroscler Rep
|
2011
|
1.10
|
|
8
|
Effects of cardiopulmonary bypass on endothelin-1-induced contraction and signaling in human skeletal muscle microcirculation.
|
Circulation
|
2010
|
1.04
|
|
9
|
Decreased contractile response to endothelin-1 of peripheral microvasculature from diabetic patients.
|
Surgery
|
2010
|
1.00
|
|
10
|
Effects of red wine and vodka on collateral-dependent perfusion and cardiovascular function in hypercholesterolemic swine.
|
Circulation
|
2012
|
0.99
|
|
11
|
Effect of hydrogen sulfide on myocardial protection in the setting of cardioplegia and cardiopulmonary bypass.
|
Interact Cardiovasc Thorac Surg
|
2010
|
0.95
|
|
12
|
Gastrointestinal complications following cardiac surgery: a comprehensive review.
|
J Card Surg
|
2010
|
0.92
|
|
13
|
Cardioprotective effects of red wine and vodka in a model of endothelial dysfunction.
|
J Surg Res
|
2012
|
0.91
|
|
14
|
Is hyperglycemia bad for the heart during acute ischemia?
|
J Thorac Cardiovasc Surg
|
2010
|
0.90
|
|
15
|
Thrombin fragment (TP508) decreases myocardial infarction and apoptosis after ischemia reperfusion injury.
|
Ann Thorac Surg
|
2009
|
0.89
|
|
16
|
The pig as a valuable model for testing the effect of resveratrol to prevent cardiovascular disease.
|
Ann N Y Acad Sci
|
2013
|
0.89
|
|
17
|
Thromboxane-induced contractile response of human coronary arterioles is diminished after cardioplegic arrest.
|
Ann Thorac Surg
|
2011
|
0.88
|
|
18
|
Trans-iliac rat aorta stenting: a novel high throughput preclinical stent model for restenosis and thrombosis.
|
J Surg Res
|
2010
|
0.87
|
|
19
|
Paclitaxel/sirolimus combination coated drug-eluting stent: in vitro and in vivo drug release studies.
|
J Pharm Biomed Anal
|
2010
|
0.86
|
|
20
|
Resveratrol supplementation abrogates pro-arteriogenic effects of intramyocardial vascular endothelial growth factor in a hypercholesterolemic swine model of chronic ischemia.
|
Surgery
|
2011
|
0.84
|
|
21
|
Effects of diabetes mellitus on VEGF-induced proliferation response in bone marrow derived endothelial progenitor cells.
|
J Card Surg
|
2010
|
0.84
|
|
22
|
Drug-eluting stents.
|
Int J Clin Exp Med
|
2010
|
0.84
|
|
23
|
Effect of thrombin fragment (TP508) on myocardial ischemia-reperfusion injury in hypercholesterolemic pigs.
|
J Appl Physiol (1985)
|
2009
|
0.84
|
|
24
|
Impact of acute myocardial ischemia reperfusion on the tissue and blood-borne renin-angiotensin system.
|
Basic Res Cardiol
|
2010
|
0.82
|
|
25
|
Does resveratrol improve insulin signaling in chronically ischemic myocardium?
|
J Surg Res
|
2013
|
0.81
|
|
26
|
Microvascular notch signaling is upregulated in response to vascular endothelial growth factor and chronic myocardial ischemia.
|
Circ J
|
2013
|
0.81
|
|
27
|
Impaired contractile response of human peripheral arterioles to thromboxane A-2 after cardiopulmonary bypass.
|
Surgery
|
2011
|
0.79
|
|
28
|
Neuropeptide Y improves myocardial perfusion and function in a swine model of hypercholesterolemia and chronic myocardial ischemia.
|
J Mol Cell Cardiol
|
2012
|
0.79
|
|
29
|
In vitro and in vivo degradation of poly(D, L-lactide-co-glycolide)/amorphous calcium phosphate copolymer coated on metal stents.
|
J Biomed Mater Res A
|
2011
|
0.79
|
|
30
|
Effect of thrombin fragment (TP508) on myocardial ischemia reperfusion injury in a model of type 1 diabetes mellitus.
|
Circulation
|
2010
|
0.78
|
|
31
|
High-fat diet alters prostanoid balance and perfusion in ischemic myocardium of naproxen-treated swine.
|
Surgery
|
2011
|
0.78
|
|
32
|
Mechanism for reduced pericardial adhesion formation in hypercholesterolemic swine supplemented with alcohol.
|
Eur J Cardiothorac Surg
|
2012
|
0.78
|
|
33
|
Local infiltration of neuropeptide Y as a potential therapeutic agent against apoptosis and fibrosis in a swine model of hypercholesterolemia and chronic myocardial ischemia.
|
Eur J Pharmacol
|
2013
|
0.77
|
|
34
|
Antiplatelet agents, warfarin, and epidemic intracranial hemorrhage.
|
Surgery
|
2010
|
0.76
|
|
35
|
Investigating the effects of resveratrol on chronically ischemic myocardium in a swine model of metabolic syndrome: a proteomics analysis.
|
J Med Food
|
2015
|
0.76
|
|
36
|
Regenerative therapies for improving myocardial perfusion in patients with cardiovascular disease: failure to meet expectations but optimism for the future.
|
Curr Vasc Pharmacol
|
2012
|
0.76
|
|
37
|
Effects of cyclooxygenase inhibition on cardiovascular function in a hypercholesterolemic swine model of chronic ischemia.
|
Am J Physiol Heart Circ Physiol
|
2011
|
0.76
|
|
38
|
Hypercholesterolemia and chronic ischemia alter myocardial responses to selective cyclooxygenase-2 inhibition.
|
J Thorac Cardiovasc Surg
|
2011
|
0.75
|
|
39
|
Effect of dimerized thrombin fragment TP508 on acute myocardial ischemia reperfusion injury in hypercholesterolemic swine.
|
J Pharmacol Exp Ther
|
2010
|
0.75
|
|
40
|
Improved biocompatibility of poly(lactic-co-glycolic acid) orv and poly-L-lactic acid blended with nanoparticulate amorphous calcium phosphate in vascular stent applications.
|
J Biomed Nanotechnol
|
2014
|
0.75
|